The SoftVue™ system developed by Delphinus Medical Technologies is a non-ionising, non-compressing, and non-invasive whole breast imaging device. Its intended use is for the examination of breasts for the presence of suspicious masses. It is not intended for use as a replacement of screening mammography.
Relugolix is a small molecule that binds to the gonadotropin-releasing hormone receptor in the pituitary gland, decreasing the release of hormones which control oestrogen and progesterone production by the ovaries. Results from clinical trials demonstrated that relugolix in combination with estradiol and norethisterone acetate reduced menstrual bleeding in women with uterine fibroids. Relugolix is administered orally, and if licensed would offer an additional treatment option for women moderate to severe symptoms associated with uterine fibroids.